7/16
07:00 am
anl
Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025
Medium
Report
Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025
7/16
06:00 am
anl
Adlai Nortye (ANL) had its "sell (e+)" rating reaffirmed by
Weiss Ratings.
Medium
Report
Adlai Nortye (ANL) had its "sell (e+)" rating reaffirmed by
Weiss Ratings.
7/13
07:00 am
anl
Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists
Medium
Report
Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists
6/22
08:00 am
anl
Adlai Nortye (ANL) is now covered by Cantor Fitzgerald. They set an "overweight" rating on the stock.
Low
Report
Adlai Nortye (ANL) is now covered by Cantor Fitzgerald. They set an "overweight" rating on the stock.
5/28
08:00 am
anl
Adlai Nortye (ANL) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating on the stock.
Low
Report
Adlai Nortye (ANL) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating on the stock.
5/14
04:46 pm
anl
Adlai Nortye (ANL) is now covered by JonesTrading. They set a "buy" rating and a $22.00 price target on the stock.
Low
Report
Adlai Nortye (ANL) is now covered by JonesTrading. They set a "buy" rating and a $22.00 price target on the stock.
5/1
04:37 am
anl
H.C. Wainwright Sees “Potential Best-in-Class Potency” for Adlai Nortye's (ANL) Lead Asset, Lifts PT [Yahoo! Finance]
Medium
Report
H.C. Wainwright Sees “Potential Best-in-Class Potency” for Adlai Nortye's (ANL) Lead Asset, Lifts PT [Yahoo! Finance]
4/29
06:17 pm
anl
Adlai Nortye: Recapitalized, Refocused, But Still Too Early To Upgrade [Seeking Alpha]
Low
Report
Adlai Nortye: Recapitalized, Refocused, But Still Too Early To Upgrade [Seeking Alpha]
4/20
07:21 am
anl
Adlai Nortye (ANL) had its "buy" rating reaffirmed by HC Wainwright.
Low
Report
Adlai Nortye (ANL) had its "buy" rating reaffirmed by HC Wainwright.